MetaCap

Myriad Genetics (MYGN) vs Achieve Life Sciences (QUIT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Achieve Life Sciences is the larger company by market cap ($573.2 million vs $523.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MYGN+79.02%QUIT-25.87%
+126%+46%-33%
Aug 17, 20261 yearNov 20, 2026
MYGN+70.62%QUIT-30.41%
+105%+34%-37%
Aug 17, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MYGN versus QUIT key metrics
MetricMYGNQUIT
Share price$5.46$5.56
Market cap$523.74M$573.25M
1-day change-1.44%-5.28%
YTD return-11.22%—
1-year return-26.02%—
5-year return-79.48%—
EPS (TTM)$-1.35$-1.71
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$824.50M—
Revenue growth (YoY)-1.56%—
Net income (latest FY)$-365.90M$-54.65M
Gross margin69.93%—
Operating margin-46.96%—
Net margin-44.38%—
52-week high$8.09$8.64
52-week low$2.74$2.62
Distance from 52-week high-32.51%-35.65%
Analyst consensusholdstrong_buy
Avg. price target upside+8.06%+162.23%
Average volume2.26M1.38M
Shares outstanding95.92M103.10M
Employees2,70028
SectorHealth CareHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesBiotechnology: In Vitro & In Vivo Diagnostic Substances

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Myriad Genetics

MYGN stock →

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. It offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,700 employees

About Achieve Life Sciences

QUIT stock →

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees

MYGN vs QUIT FAQ

Which is bigger, Myriad Genetics or Achieve Life Sciences?

Achieve Life Sciences (QUIT) is larger, with a market capitalization of $573.25M compared with $523.74M for Myriad Genetics (MYGN).

Are Myriad Genetics and Achieve Life Sciences in the same industry?

Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.

More comparisons